Mankind Pharma Ltd

Mankind Pharma Ltd

Mankind Pharma Ltd has announced its Q2 & H1 FY27 earnings, with revenue increasing 17% year-on-year to Rs. 4,338 crores, and EBITDA margin improving by 210 bps year-on-year to 27.1%. The company's BSVs portfolio continued its 20%+ growth momentum for the second consecutive quarter, driven by strong performance in both domestic and international markets.

Mankind Pharma Ltd

Mankind Pharma Ltd has announced that CRISIL has reaffirmed/withdrawn credit ratings for certain instruments, including non-convertible debentures and commercial paper. The ratings for non-convertible debentures worth ₹40 crore and ₹2,100 crore were reaffirmed, while the ratings for non-convertible debentures worth ₹2,500 crore and commercial paper worth ₹1,500 crore were withdrawn.

Mankind Pharma Ltd

Mankind Pharma Ltd has released an investor presentation for its Analyst / Institutional Investors meet, highlighting its growth trajectory, market leadership, commercial reach, R&D journey, manufacturing evolution, and transformation initiatives.

Mankind Pharma Ltd

Mankind Pharma Ltd has announced unaudited financial results for the quarter and half year ended September 30, 2026. The company reported revenue from operations of ₹4,337.86 crore, profit for the period/year before exceptional items and tax of ₹929.11 crore, and profit for the period/year after exceptional items and tax of ₹716.12 crore. The company also declared an income distribution cum capital withdrawal of ₹17.23 per equity share.

Mankind Pharma Ltd

Mankind Pharma Ltd has made the audio recording of its Investor Conference Call held on October 26, 2026, available for access.

Mankind Pharma Ltd

Mankind Pharma Ltd has announced its investor presentation on financial results for Q2 & H1 FY27, showcasing a 17.3% YoY growth in revenue, with EBITDA margins improving by 210 bps to 27.1%. The company's domestic business grew 15.9% YoY, driven by strong double-digit growth in both Mankind and BSV specialty business. Key brands like Pantakind, Dydroboon, and Cefakind-CV showed significant growth in Q2FY27.

Mankind Pharma Ltd

Mankind Pharma Ltd reported a 17% YoY growth in revenue, 27% YoY growth in EBITDA, and 38% YoY growth in PAT for Q2 FY27. Domestic business grew 16% YoY, driven by strong double-digit growth in Mankind and BSV specialty business. The company also announced a 33% YoY growth in international revenue.

Mankind Pharma Ltd

Mankind Pharma Ltd has approved the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. The company has also considered and approved the Scheme of Arrangement for amalgamation of its wholly owned subsidiaries with the company, subject to necessary statutory and regulatory approvals.

Mankind Pharma Ltd

Mankind Pharma Ltd approved the unaudited Standalone and Consolidated Financial Results for the quarter and half year ended on September 30, 2026. The company also considered and approved the Scheme of Arrangement for amalgamation of its wholly owned subsidiaries with the company.

Mankind Pharma Ltd

Mankind Pharma Ltd has approved its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. The company has also considered and approved the Scheme of Arrangement for amalgamation of its wholly owned subsidiaries with the company. The scheme is subject to receipt of requisite statutory, regulatory, and other approvals.

Mankind Pharma Ltd

Mankind Pharma Ltd has announced its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, and has also approved the Scheme of Amalgamation for the merger of its wholly owned subsidiaries Prolijune Lifesciences Private Limited and Pavi Buildwell Private Limited with itself, and also considered and noted the Scheme of Amalgamation for the merger of Upakarma Ayurveda Private Limited with its wholly owned subsidiary Mankind Consumer Products Private Limited.

Mankind Pharma Ltd

Mankind Pharma Ltd has approved its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. The company has also considered and approved the Scheme of Arrangement for amalgamation of its wholly owned subsidiaries with the company, and taken note of the Scheme of Arrangement for amalgamation of another wholly owned subsidiary with the company.

Mankind Pharma Ltd

Mankind Pharma Ltd has rescheduled its earnings conference call for Q2 & H1 FY27 due to unavoidable circumstances, changing the time from 6:00 PM to 5:00 PM on October 26, 2026.

Mankind Pharma Ltd

Mankind Pharma Ltd has announced an Analyst/Institutional Investors Meet on October 27, 2026, in Mumbai, to be attended by senior management and members of the leadership team of Armed Cell Therapeutics (ACTx).

Mankind Pharma Ltd

Mankind Pharma Ltd has rescheduled its Earnings Conference Call for Q2 & H1 FY27 due to unavoidable circumstances, from 06:00 P.M. (IST) on October 26, 2026, to 05:00 P.M. (IST) on the same date.

Mankind Pharma Ltd

Mankind Pharma Ltd has paid interest and redeemed Non-Convertible Debentures (NCDs) to its holders on October 16, 2026, as per Regulation 57(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Mankind Pharma Ltd

Mankind Pharma Ltd has been assigned an ESG rating of '71' by NSE Sustainability, a SEBI registered ESG Rating Provider, for FY26 based on publicly available information.

Mankind Pharma Ltd

Mankind Pharma Ltd has announced that its Board of Directors has approved the acquisition of a majority stake (70%) in Armed Cell Therapeutics B.V. (ACTx), a Belgium-incorporated biotechnology company, through its wholly-owned subsidiary Mankind Pharma (Netherlands) B.V. The acquisition is part of the company's long-term strategy to build a global innovation-led pharmaceutical business.

Mankind Pharma Ltd

Mankind Pharma Ltd has announced an investment of up to EUR 45Mn in its wholly-owned subsidiary Mankind Pharma (Netherlands) B.V. to acquire a 70% stake in Armed Cell Therapeutics B.V. (ACTx), a Belgium-incorporated biotechnology company developing next-generation CAR-T therapies for cancer.

Mankind Pharma Ltd

Mankind Pharma Ltd has approved an additional investment of up to EUR 45Mn in Mankind Pharma (Netherlands) B.V. and acquired a majority stake (70%) in Armed Cell Therapeutics B.V. through Mankind Netherlands. The investment will be utilized to acquire a 70% stake in ACTx, a biotechnology company developing next-generation CAR-T therapies for cancer.